Innovent Biologics (IVBIY) Stock Price, Quote, News & History

Innovent Biologics Inc (IVBIY) Stock Price, Quote, News & History

IVBIYOTCPK

Trade with Public

$44.15

At close: Apr 17, 5:00 PM EST

Key Statistics

Open

Volume / Avg.

0 / 450.00

Day Range

- - -

52 Wk Range

25.42 - 52.00

Market Cap

$18.99B

P/E Ratio

160.08

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

Recent Innovent Biologics Inc News

FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting

The

Vandana Singh

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.

Vandana Singh

Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.82B

Investing Cash Flow (TTM)

-66.93M

Financing Cash Flow (TTM)

302.60M

Free Cash Flow (TTM)

581.01M

Capital Expenditure (TTM)

-1.24B

Net Change in Cash (TTM)

2.05B

Valuation Metrics

Enterprise Value

$17.87B

PE Ratio (TTM)

160.08

PE Ratio (FWD)

62.11

PEG Ratio (TTM)

PS Ratio (TTM)

10.04

PB Ratio (TTM)

6.69

Earnings Yield % (TTM)

0.62%

Earnings Yield % (FWD)

1.61%

EV / EBITDA (TTM)

133.90

Price / EBITDA (TTM)

142.62

Price / Free Cash Flow (TTM)

225.46

Book Value / Share

$6.60

Company Debt

Total Debt

$3.37B

LT Debt

$2.26B

LT Debt Issuance (TTM)

$1.92B

LT Debt Repayment (TTM)

-$1.75B

Total Cash

$9.54B

Debt to Equity

0.15

Issuance of Debt (TTM)

$166.21M

Repayment of Debt (TTM)

-$1.75B

Key Statistics

Open

Volume / Avg.

0 / 450.00

Day Range

- - -

52 Wk Range

25.42 - 52.00

Market Cap

$18.99B

P/E Ratio

160.08

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

About

Sector

Health Care

Industry

Biotechnology

Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Innovent Biologics (IVBIY) stock?

You can purchase shares of Innovent Biologics (OTCPK:IVBIY) through any online brokerage.

View our list of the best stock brokerages

Who are Innovent Biologics (IVBIY) competitors?

There are no as such competitors for Innovent Biologics.

What is the forecast, or price target, for Innovent Biologics (IVBIY) stock?

There is no analysis for Innovent Biologics to provide a consensus price target.

What is the current price for Innovent Biologics (IVBIY)?

The stock price for Innovent Biologics (OTCPK: IVBIY) is $44.15 last updated April 10, 2026 at 3:09 PM EDT.

Does Innovent Biologics (IVBIY) pay a dividend?

There are no upcoming dividends for Innovent Biologics.

When is Innovent Biologics (OTCPK:IVBIY) reporting earnings?

Innovent Biologics does not have any upcoming earnings scheduled.

Is Innovent Biologics (IVBIY) going to split?

There is no upcoming split for Innovent Biologics.

What sector and industry does Innovent Biologics (IVBIY) operate in?

Innovent Biologics is in the Health Care sector and Biotechnology industry. They are listed on the OTCPK.

Key Statistics

Open

Volume / Avg.

0 / 450.00

Day Range

- - -

52 Wk Range

25.42 - 52.00

Market Cap

$18.99B

P/E Ratio

160.08

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

Recent Innovent Biologics Inc News

FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting

The

Vandana Singh

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

Vandana Singh

Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.82B

Investing Cash Flow (TTM)

-66.93M

Financing Cash Flow (TTM)

302.60M

Free Cash Flow (TTM)

581.01M

Capital Expenditure (TTM)

-1.24B

Net Change in Cash (TTM)

2.05B

Valuation Metrics

Enterprise Value

$17.87B

PE Ratio (TTM)

160.08

PE Ratio (FWD)

62.11

PEG Ratio (TTM)

PS Ratio (TTM)

10.04

PB Ratio (TTM)

6.69

Earnings Yield % (TTM)

0.62%

Earnings Yield % (FWD)

1.61%

EV / EBITDA (TTM)

133.90

Price / EBITDA (TTM)

142.62

Price / Free Cash Flow (TTM)

225.46

Book Value / Share

$6.60

Company Debt

Total Debt

$3.37B

LT Debt

$2.26B

LT Debt Issuance (TTM)

$1.92B

LT Debt Repayment (TTM)

-$1.75B

Total Cash

$9.54B

Debt to Equity

0.15

Issuance of Debt (TTM)

$166.21M

Repayment of Debt (TTM)

-$1.75B

Key Statistics

Open

Volume / Avg.

0 / 450.00

Day Range

- - -

52 Wk Range

25.42 - 52.00

Market Cap

$18.99B

P/E Ratio

160.08

Dividend Yield

Exchange

OTC

RSI

Short Interest

Days to Cover

About

Sector

Health Care

Industry

Biotechnology

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Innovent Biologics (IVBIY) stock?

You can purchase shares of Innovent Biologics (OTCPK:IVBIY) through any online brokerage.

View our list of the best stock brokerages

Who are Innovent Biologics (IVBIY) competitors?

There are no as such competitors for Innovent Biologics.

What is the forecast, or price target, for Innovent Biologics (IVBIY) stock?

There is no analysis for Innovent Biologics to provide a consensus price target.

What is the current price for Innovent Biologics (IVBIY)?

The stock price for Innovent Biologics (OTCPK: IVBIY) is $44.15 last updated April 10, 2026 at 3:09 PM EDT.

Does Innovent Biologics (IVBIY) pay a dividend?

There are no upcoming dividends for Innovent Biologics.

When is Innovent Biologics (OTCPK:IVBIY) reporting earnings?

Innovent Biologics does not have any upcoming earnings scheduled.

Is Innovent Biologics (IVBIY) going to split?

There is no upcoming split for Innovent Biologics.

What sector and industry does Innovent Biologics (IVBIY) operate in?

Innovent Biologics is in the Health Care sector and Biotechnology industry. They are listed on the OTCPK.